1. Home
  2. KYN vs AUPH Comparison

KYN vs AUPH Comparison

Compare KYN & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kayne Anderson Energy Infrastructure Fund Inc.

KYN

Kayne Anderson Energy Infrastructure Fund Inc.

HOLD

Current Price

$13.61

Market Cap

2.4B

Sector

Finance

ML Signal

HOLD

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

HOLD

Current Price

$15.08

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KYN
AUPH
Founded
2004
1993
Country
United States
Canada
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.0B
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
KYN
AUPH
Price
$13.61
$15.08
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$17.25
AVG Volume (30 Days)
417.2K
1.1M
Earning Date
01-01-0001
05-07-2026
Dividend Yield
8.99%
N/A
EPS Growth
N/A
5075.00
EPS
0.71
0.25
Revenue
N/A
$283,055,000.00
Revenue This Year
N/A
$17.54
Revenue Next Year
N/A
$15.74
P/E Ratio
$19.48
$61.48
Revenue Growth
N/A
20.38
52 Week Low
$11.31
$7.29
52 Week High
$14.70
$16.88

Technical Indicators

Market Signals
Indicator
KYN
AUPH
Relative Strength Index (RSI) 39.55 43.85
Support Level $12.93 $14.53
Resistance Level $14.37 $15.23
Average True Range (ATR) 0.25 0.53
MACD -0.07 -0.07
Stochastic Oscillator 3.16 7.20

Price Performance

Historical Comparison
KYN
AUPH

About KYN Kayne Anderson Energy Infrastructure Fund Inc.

Kayne Anderson Energy Infrastructure Fund, Inc is a non-diversified, closed-end fund. Its investment objective is to provide a high after-tax total return with an emphasis on making cash distributions to the stockholder. The Company invests in various sectors, which include midstream energy companies, renewable infrastructure companies, and utility companies. The company seeks to achieve its objectives by investing a majority of its total assets in the securities of Energy Infrastructure companies.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: